Investor Manning Paul B
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Manning Paul B . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-06-03 13D/A TSHA / Taysha Gene Therapies, Inc. 23,476,333 25,601,111
2024-11-26 13D/A VRCA / Verrica Pharmaceuticals Inc. 15,389,481 52,504,049
2024-11-12 13G/A LQDA / Liquidia Corporation 6,328,721 6,679,132
2024-02-14 13G/A LQDA / Liquidia Corporation 6,024,113 6,328,721
2023-08-21 13D/A TSHA / Taysha Gene Therapies, Inc. 6,989,861 23,476,333
2023-02-15 13G/A KTTA / Pasithea Therapeutics Corp. 3,408,696 3,408,696
2023-02-14 13G/A ABOS / Acumen Pharmaceuticals, Inc. 4,010,678 3,205,128
2023-02-14 13G/A LQDA / Liquidia Corporation 5,175,172 6,024,113
2022-11-02 13D/A TSHA / Taysha Gene Therapies, Inc. 5,295,307 6,989,861
2022-07-15 13D VRCA / Verrica Pharmaceuticals Inc. 10,627,577 15,389,481
2022-06-29 13G KTTA / Pasithea Therapeutics Corp. 3,408,696
2022-02-15 13G ABOS / Acumen Pharmaceuticals, Inc. 4,010,678
2022-02-14 13G/A VRCA / Verrica Pharmaceuticals Inc. 9,837,747 10,627,577
2022-02-14 13D CADL / Candel Therapeutics, Inc. 4,073,316
2022-02-14 13G/A LQDA / Liquidia Corporation 4,942,041 5,175,172
2021-02-16 13G/A VRCA / Verrica Pharmaceuticals Inc. 9,643,247 9,837,747
2021-02-16 13G LQDA / Liquidia Corporation 4,942,041
2020-10-05 13D TSHA / Taysha Gene Therapies, Inc. 5,295,307
2020-02-03 13G/A VRCA / Verrica Pharmaceuticals Inc. 9,643,247 9,643,247
2020-01-31 13G/A VRCA / Verrica Pharmaceuticals Inc. 9,574,861 9,643,247
2019-02-06 13G VRCA / Verrica Pharmaceuticals Inc. 9,574,861
2019-02-06 13G/A DOVA / Dova Pharmaceuticals, Inc. 14,124,049 14,666,180
2018-02-13 13G DOVA / Dova Pharmaceuticals, Inc. 14,124,049